Brain Health & Nootropics
Route(s)
Subcutaneous, Intranasal
Typical dose
100-200 mcg
Dosing window
Morning
Receptor / target
Melanocortin receptors / Enhanced BDNF up-regulation
Properties
Half-life: ~1 to 2 hours
Pre-mixed
No
Adamax
← Back to Library
Protocol not independently verified Neural Cognitive
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Compound Profile
Adamax is reviewed here for cognition, mood, and brain-health context.
Research Summary
Evidence Strength
Limited
Primary Evidence
Published literature searches and source-listed protocols
Research Focus
Cognition, Mood, Brain health
Mechanism
Target context: Melanocortin receptors / Enhanced BDNF up-regulation
Long-Term Data
Limited or not established.
Current Consensus
Treat protocols as educational examples unless stronger sources are listed.
Route(s)
Subcutaneous, Intranasal
Typical dose
100-200 mcg
Dosing window
Morning
Receptor / target
Melanocortin receptors / Enhanced BDNF up-regulation
Properties
Half-life: ~1 to 2 hours
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-8 | 100-200 mcg 1x Daily | Standard cognitive enhancement protocol. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 300 mcg 1x Daily | Initiation phase. |
| Weeks 3-4 | 500 mcg 1x Daily | Escalation phase. |
| Weeks 5-6 | 750 mcg 1x Daily | Advanced cognitive drive. |
| Weeks 7-8 | 1000 mcg 1x Daily | Peak saturation phase. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Nootropic protocols are state-dependent: sleep, anxiety, stimulants, psychiatric history, and route can change the response. The logic is morning-biased, low-entry dosing, and stopping if arousal or mood destabilizes. Entry context: target (Melanocortin receptors / Enhanced BDNF up-regulation); route Subcutaneous/Intranasal; timing Morning. Unapproved or unverified dosing examples are hypotheses, not recommendations. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added.
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied in neuroprotection, cognition, anxiety, sleep, stroke, neuropathy, or neuropeptide models depending on the target and route. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: Melanocortin receptors / Enhanced BDNF up-regulation. Route(s): Subcutaneous, Intranasal. Dosing window on page: Morning. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- Nootropic and neuropeptide claims need separation between animal neuroprotection, regional clinical literature, and modern randomized human trials.
- Sleep, anxiety, psychiatric history, blood pressure, and route-specific delivery are common practical limits.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Weeks 1-8, 100-200 mcg 1x Daily; Alternative Titration 1: Weeks 1-2, 300 mcg 1x Daily.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor sleep, anxiety or mood activation, blood pressure, seizure history, psychiatric history, and route-specific nasal or injection irritation.
Selected medical sources
Independent evidence
Independent safety notes: No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Concurrent Semax use: Adamax is a pharmacokinetically superior derivative of Semax acting on identical TrkB/MC4R/BDNF targets; co-administration produces supraphysiological receptor agonism without incremental benefit while amplifying all stimulant-adjacent adverse effects and accelerating TrkB downregulation; these compounds are absolutely mutually exclusive.
- Severe anxiety disorders or active panic disorder: Adamax's enhanced CNS penetration amplifies the MC4R-driven dopaminergic activation and arousal effects of the Semax pharmacophore significantly beyond what parent Semax produces; subjects with anxiety disorders may experience pronounced worsening.
- Active manic episode or bipolar I disorder (manic phase): dopaminergic and noradrenergic amplification from high-CNS-penetrance MC4R agonism can trigger or accelerate manic states in susceptible individuals.
- Active psychotic disorders: contraindicated for the same reasons as Semax, with greater urgency given the amplified CNS potency.
- Late-day administration (after noon): the half-life of 1-2 hours means direct receptor activity clears reasonably quickly, but the BDNF transcription and MC4R-driven arousal effects persist several hours; evening administration reliably causes insomnia.
- Known hypersensitivity to Semax, Adamax, adamantane-modified peptides, or formulation excipients.
- Concurrent MAOI use: dopaminergic and serotonergic potentiation via MC4R creates serotonin/dopamine excess risk in the presence of monoamine oxidase inhibition.
- Pregnancy: no safety data; BDNF signaling plays critical roles in fetal neural development; exogenous supraphysiological BDNF stimulation in utero is not established as safe.
- Breastfeeding: no safety data.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Overstimulation: the most expected and dose-dependent adverse effect; characterized by racing thoughts, mental hyperactivity, inability to relax, mild euphoria at higher doses; a direct consequence of amplified MC4R-driven dopaminergic and noradrenergic tone from high CNS-penetrant delivery; managed with dose reduction or Selank co-administration.
- Insomnia: MC4R arousal activation persists several hours beyond the short plasma half-life; any administration after noon or at doses above individual tolerance reliably produces sleep onset difficulty; morning-only strict dosing is the primary management.
- Increased resting heart rate: mild tachycardia from adrenergic-adjacent MC4R activation; generally 5-10 BPM above baseline; typically well-tolerated but warrants monitoring.
- Anxiety and irritability: common at doses above individual tolerance; mechanistically identical to Semax anxiety but with greater intensity due to enhanced CNS delivery.
- Headache: reported in the initiation phase; possibly related to rapid changes in BDNF-driven cerebrovascular tone; typically self-limiting within the first week.
- Hair shedding (rare): BDNF elevation from Adamax, amplified relative to Semax, can accelerate hair follicle cycling and produce transient telogen effluvium; same mechanism as documented with Semax but potentially more pronounced.
- TrkB receptor downregulation: the primary long-term risk of sustained high-dose administration without adequate washout; results in diminished response to subsequent Adamax or Semax cycles; the 4-week washout protocol is the mitigation strategy.
- Nasal irritation: with intranasal administration specifically; not applicable to subcutaneous route.
- Mild blood pressure elevation: from adrenergic-adjacent MC4R/dopaminergic activation; rarely clinically significant at standard doses but warrants monitoring in subjects with cardiovascular risk factors.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: